Emile D. Kerver

3.5k total citations
10 papers, 238 citations indexed

About

Emile D. Kerver is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Emile D. Kerver has authored 10 papers receiving a total of 238 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Emile D. Kerver's work include Radiopharmaceutical Chemistry and Applications (3 papers), Colorectal Cancer Treatments and Studies (3 papers) and Prostate Cancer Treatment and Research (3 papers). Emile D. Kerver is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (3 papers), Colorectal Cancer Treatments and Studies (3 papers) and Prostate Cancer Treatment and Research (3 papers). Emile D. Kerver collaborates with scholars based in Netherlands, United States and Gabon. Emile D. Kerver's co-authors include Vincent van der Noort, Maartje Los, Andries M. Bergman, Jules L.L.M. Coenen, Paul Hamberg, Igle J. de Jong, Alfons J.M. van den Eertwegh, H. Pieter van den Berg, Inge M. van Oort and Harm van Tinteren and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Emile D. Kerver

10 papers receiving 237 citations

Peers

Countries citing papers authored by Emile D. Kerver

Since Specialization

Citations

This map shows the geographic impact of Emile D. Kerver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emile D. Kerver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emile D. Kerver more than expected).

Fields of papers citing papers by Emile D. Kerver

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emile D. Kerver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emile D. Kerver. The network helps show where Emile D. Kerver may publish in the future.

Co-authorship network of co-authors of Emile D. Kerver

This figure shows the co-authorship network connecting the top 25 collaborators of Emile D. Kerver. A scholar is included among the top collaborators of Emile D. Kerver based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emile D. Kerver. Emile D. Kerver is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancreatic cancer 2025 ·Med ·(unknown), Mark P.G. Dings, Jan Köster, Mariëtte Labots, Emile D. Kerver, Anouk Jochems, Marjolein Y.V. Homs, Judith de Vos‐Geelen, Mathijs P. Hendriks, Michael W.T. Tanck, Johanna W. Wilmink, Hanneke W. M. van Laarhoven, Maarten F. Bijlsma	1
2	Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP) 2024 ·European Journal of Cancer ·(unknown), Laurien J. Zeverijn, Birgit S. Geurts, (unknown), (unknown), Vincent van der Noort, Paul Roepman, Wendy W.J. de Leng, (unknown), Elske C. Gootjes, (unknown), Emile D. Kerver, Theo van Voorthuizen, Jeanine M.L. Roodhart, Liselot Valkenburg‐van Iersel, Hans Gelderblom, Emile E. Voest, Henk M.W. Verheul	6
3	LBA27 First-line systemic treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM): Overall survival of the phase III CAIRO5 study of the Dutch Colorectal Cancer Group 2023 ·Annals of Oncology ·Cornelis J.A. Punt, Marinde J. G. Bond, Karen Bolhuis, O. J. L. Loosveld, Jan Willem de Groot, Helga Droogendijk, Helgi H. Helgason, Mathijs P. Hendriks, Joost M. Klaase, Geert Kazemier, Mike S.L. Liem, Arjen M. Rijken, Cornelis Verhoef, Johannes H. W. de Wilt, Koert P. de Jong, (unknown), B. De Valk, Emile D. Kerver, (unknown), (unknown)	4
4	Platelet Transfusion before CVC Placement in Patients with Thrombocytopenia 2023 ·New England Journal of Medicine ·(unknown), (unknown), Walter J. F. M. van der Velden, (unknown), Pieter R. Tuinman, Paula F. Ypma, Walter M. van den Bergh, (unknown), Emile D. Kerver, A.J. Gerard Jansen, Peter E. Westerweel, M. Sesmu Arbous, Rogier M. Determann, Walther van Mook, Mirelle Koeman, (unknown), Krijn P. van Lienden, Jan M. Binnekade, Bart J. Biemond, Alexander P. J. Vlaar	26
5	FOLFOXIRI + bevacizumab versus FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases (CRLM) and right-sided and/or RAS/BRAFV600E-mutated primary tumor: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group. 2022 ·Journal of Clinical Oncology ·Cornelis J.A. Punt, Marinde J. G. Bond, Karen Bolhuis, O. J. L. Loosveld, Helgi H. Helgason, Jan Willem de Groot, Mathijs P. Hendriks, Emile D. Kerver, Mike S.L. Liem, Arjen M. Rijken, Cornelis Verhoef, Johannes H.W. de Wilt, Koert P. de Jong, Geert Kazemier, Martinus J. van Amerongen, Marc Engelbrecht, Joost M. Klaase, (unknown), Marta López‐Yurda, Rutger‐Jan Swijnenburg	7
6	MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis 2019 ·Haematologica ·Joost S.P. Vermaat, (unknown), Liesbeth C. de Wreede, Willem Kraan, Ruben A. L. de Groen, Anne M.R. Schrader, Emile D. Kerver, Cornelis G. Scheepstra, Henriette W Berenschot, Wendy Deenik, Jurgen Wegman, (unknown), (unknown), Marcel Nijland, Tom van Wezel, Hendrik Veelken, Marcel Spaargaren, Arjen H.G. Cleven, Marie José Kersten, Steven T. Pals	57
7	Outcome effects of antiretroviral drug combinations in HIV-positive patients with chemotherapy for lymphoma: a retrospective analysis 2018 ·International Journal of Clinical Pharmacy ·Ferdi Sombogaard, Eric J. F. Franssen, Wim Terpstra, Emile D. Kerver, G.E.L. van den Berk, Mirjam Crul	8
8	Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer 2016 ·Oncology ·(unknown), Vincent van der Noort, Paul Hamberg, Jules L.L.M. Coenen, Maureen J.B. Aarts, Inge M. van Oort, Alfons J.M. van den Eertwegh, Maartje Los, H. Pieter van den Berg, Hans Gelderblom, Suzan Vrijaldenhoven, Emile D. Kerver, Theo van Voorthuizen, Igle J. de Jong, John B.A.G. Haanen, Andries M. Bergman, (unknown)	10
9	Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration‐resistant prostate cancer patients; a possible time relation 2015 ·The Prostate ·(unknown), Vincent van der Noort, Alfons J.M. van den Eertwegh, Paul Hamberg, Inge M. van Oort, H. Pieter van den Berg, Maartje Los, Maureen J.B. Aarts, Jules L.L.M. Coenen, Hans Gelderblom, Igle J. de Jong, Emile D. Kerver, Suzan Vrijaldenhoven, Theo van Voorthuizen, Fabienne Warmerdam, John B.A.G. Haanen, Andries M. Bergman, (unknown)	10
10	Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment 2013 ·Cancer ·(unknown), Vincent van der Noort, Inge M. van Oort, H. Pieter van den Berg, Maartje Los, Paul Hamberg, Jules L.L.M. Coenen, Alfons J.M. van den Eertwegh, Igle J. de Jong, Emile D. Kerver, Harm van Tinteren, Andries M. Bergman	109

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact